对“吲哚类磷脂酶D抑制剂用于肺癌免疫治疗的开发与评价”的更正

IF 6.8 1区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Medicinal Chemistry Pub Date : 2025-09-26 DOI:10.1021/acs.jmedchem.5c02366

Doona Song, Seong Hun Lim, Yeji Kim, Hyesung Lee, Taehyun Kim, Hocheol Lim, Do Sik Min, Gyoonhee Han

{"title":"对“吲哚类磷脂酶D抑制剂用于肺癌免疫治疗的开发与评价”的更正","authors":"Doona Song, Seong Hun Lim, Yeji Kim, Hyesung Lee, Taehyun Kim, Hocheol Lim, Do Sik Min, Gyoonhee Han","doi":"10.1021/acs.jmedchem.5c02366","DOIUrl":null,"url":null,"abstract":"The Acknowledgments section was corrected to change: ‘This research was supported by the [Bio&Medical Technology Development Program] of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00222838, RS-2023-00219297, and 2023R1A2C100530811).’ to ‘This research was supported by the [Bio&Medical Technology Development Program] of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00222838, RS-2023-00219297, and RS-2023-NR076630).’ This article has not yet been cited by other publications.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"18 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to “Development and Evaluation of Indole-Based Phospholipase D Inhibitors for Lung Cancer Immunotherapy”\",\"authors\":\"Doona Song, Seong Hun Lim, Yeji Kim, Hyesung Lee, Taehyun Kim, Hocheol Lim, Do Sik Min, Gyoonhee Han\",\"doi\":\"10.1021/acs.jmedchem.5c02366\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Acknowledgments section was corrected to change: ‘This research was supported by the [Bio&Medical Technology Development Program] of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00222838, RS-2023-00219297, and 2023R1A2C100530811).’ to ‘This research was supported by the [Bio&Medical Technology Development Program] of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00222838, RS-2023-00219297, and RS-2023-NR076630).’ This article has not yet been cited by other publications.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c02366\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c02366","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

致谢部分更正为：“本研究得到韩国政府（MSIT）资助的国家研究基金会（NRF）[生物医疗技术开发计划]的支持。RS-2023-00222838, RS-2023-00219297，和2023R1A2C100530811)。这项研究得到了韩国政府（MSIT）资助的国家研究基金会（NRF）[生物医疗技术开发计划]的支持。RS-2023-00222838， RS-2023-00219297和RS-2023-NR076630)。这篇文章尚未被其他出版物引用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to “Development and Evaluation of Indole-Based Phospholipase D Inhibitors for Lung Cancer Immunotherapy”

The Acknowledgments section was corrected to change: ‘This research was supported by the [Bio&Medical Technology Development Program] of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00222838, RS-2023-00219297, and 2023R1A2C100530811).’ to ‘This research was supported by the [Bio&Medical Technology Development Program] of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00222838, RS-2023-00219297, and RS-2023-NR076630).’ This article has not yet been cited by other publications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.